tiprankstipranks
Advertisement
Advertisement

APRE Stock Latest News

Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
Company AnnouncementsAprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
9m ago
APRE
Aprea Shareholders Approve Directors, Reverse Split Flexibility
PremiumCompany Announcements
Aprea Shareholders Approve Directors, Reverse Split Flexibility
2M ago
8K
APRE
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
PremiumRatings
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
2M ago
APRE
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
PremiumRatings
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
3M ago
APRE
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
PremiumThe Fly
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
3M ago
APRE
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
PremiumThe FlyAprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
3M ago
APRE
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
Premium
Company Announcements
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
3M ago
8K
APRE
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
Premium
The Fly
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
3M ago
ABX
CNH
Aprea Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Aprea Therapeutics initiated with an Outperform at Oppenheimer
3M ago
APRE
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
PremiumThe Fly
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
3M ago
APRE
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
PremiumRatings
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
4M ago
APRE
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
PremiumCompany Announcements
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
4M ago
8K
APRE
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
PremiumThe FlyAprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
4M ago
APRE
Aprea Therapeutics Announces $30 Million Private Placement
Premium
Company Announcements
Aprea Therapeutics Announces $30 Million Private Placement
4M ago
8K
APRE
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
Premium
The Fly
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
4M ago
APRE
Aprea Highlights Early APR-1051 Data and Financial Update
PremiumCompany Announcements
Aprea Highlights Early APR-1051 Data and Financial Update
5M ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
PremiumThe Fly
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
5M ago
APRE
Aprea Therapeutics sees cash runway into 1Q27
PremiumThe Fly
Aprea Therapeutics sees cash runway into 1Q27
5M ago
APRE
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
PremiumThe Fly
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
6M ago
APRE
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
PremiumRatingsAprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
6M ago
APRE
Aprea Highlights Encouraging Phase 1 Data for APR-1051
Premium
Company Announcements
Aprea Highlights Encouraging Phase 1 Data for APR-1051
6M ago
8K
APRE
Aprea Therapeutics announces additional clinical activity for APR-1051
Premium
The Fly
Aprea Therapeutics announces additional clinical activity for APR-1051
6M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >